Status and phase
Conditions
Treatments
About
This is a Phase 2, multicenter, randomized, open-lable study to evaluate the efficacy and safety of luspatercept (ACE-536) for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS)in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosed of primary myelodysplastic syndrome with a PISS-R grading of very low, low or intermediate risk and a bone marrow primitive cell count < 5%, the time frame for this grading assessment should be at least 12 weeks prior to the first dose
Non-5q(del)-associated myelodysplastic syndrome.
Two non-transfused hemoglobin ≥ 6.0 g/dL and < 10.0 g/dL, averaged over the screening period, at least one week and more apart, and with no more than 1.3 g/dL difference between the two Hb.
Non-transfused subjects (NTD cohort) defined as no red blood cell transfusion in the 16 weeks prior to randomization or low transfusion load subjects defined as 3-7 pRBC units transfused in the 16 weeks prior to randomization and at least two different time points (LTB-1 cohort) or 1-2 pRBC units transfused at one time point in the 16 weeks prior to randomization ( LTB-2 cohort) (except in the case of transfusion for treatment of other comorbidities such as blood loss, surgery, etc.);
Baseline EPO level ≤ 500 mU/mL
Platelets ≥ 30,000 /mm3 and absolute neutrophil count ≥ 800/mm3
Adequate liver function with:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
63 participants in 3 patient groups
Loading...
Central trial contact
Yusha Zhu, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal